Providers/Grant Support
This activity is supported by an independent education grant from Lilly.
Credits Available
This activity does not offer credit.
Target Audience
This activity is designed to meet the educational needs of Imaging physicians, including Nuclear Medicine Physicians, Radiologists, Neuroradiologists, Radiology Physician Assistants, Imaging Residents. It is also suitable for Neurologists.
Program Overview
As the landscape of Alzheimer’s disease continues to evolve, PET imaging is playing an increasingly critical role in early and accurate diagnosis, disease staging, and treatment decision-making. But how can nuclear medicine and radiology physicians effectively integrate PET imaging into clinical practice while navigating regional variations, emerging tracers, and evolving guidelines?
This activity will cover the latest insights, practical strategies, and real-world case studies on PET imaging in Alzheimer’s disease. Featuring leading experts from Europe, Asia, and the USA, this program will provide a global perspective on best practices, challenges, and decision-making tools to optimize patient care.
Put your decision-making and interpretation skills into practice in a simulated environment. Presented with different patient characteristics, you will be challenged to choose the optimal tracer, accurately interpret the results, and advise on next steps.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Integrate best practice for the selection, interpretation, and reporting of PET biomarkers in the context of your local clinical practice
- Incorporate optimal communication and reporting methods to enhance interdisciplinary working and patient relationships
Faculty
Dr Ana M Franceschi
Associate Professor of Radiology
Lennox Hill Hospital, NY, USA
Dr. Ana Franceschi serves as Director of Dementia Imaging at Lenox Hill Hospital/Northwell Health and is an Associate Professor of Radiology at the Barbara and Donald Zucker School of Medicine at Hofstra/Northwell. Dr. Franceschi has developed a special emphasis on the advancement of brain PET/MRI and hybrid imaging techniques in dementia and neurodegenerative disease. Dr. Franceschi was awarded the 2021 Foundation of the ASNR Boerger Research Fund for Alzheimer’s Disease and Neurocognitive Disorders for the project “[18F] PI-2620 in Primary Progressive Aphasia,” with the goal of characterizing biodistribution of abnormal tau accumulation in PPA subtypes using the novel second generation tracer PI-2620 and correlating these findings with clinical disease severity and neurodegeneration. She is also PI for the project “Utility of [18F] PI-2620 as Universal Biomarker for the A/T/N Classification of Dementia and Neurodegenerative Disease”, which aims to establish the efficacy of PI-2620 as a single, universal biomarker for the A/T/N classification scheme of dementia. In addition to multiple scientific publications on this topic, Dr. Franceschi is the lead editor of the textbook Hybrid PET/MR Neuroimaging: A Comprehensive Approach (Springer Nature, 2022). She serves as the Senior Editor for the Molecular Imaging section of the AJNR, Chair of the ACR’s Dementia Workgroup, and contributes to leadership decisions as a member of the AJNR and WJNM Editorial Boards.
Disclosures of Conflicts of Interest
Dr Ana M Franceschi
Honoraria/Consultation fees from Biogen, Eisai, Eli Lilly, Roche, Siemens Healthineers, MIM Software, Cardinal Health, Life Molecular Imaging, Blue Earth Diagnostics, Icometrix, Cortechs, PeerView.
Instructions for Participation
There are no fees for participating in this enduring activity. Read the information and faculty disclosures, participate in this online activity, and submit the evaluation form.
Disclosure of Unlabeled Use
Faculty participating in any CME activity are required to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For questions please contact ime@springer.com